974 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
PFE Pfizer, Inc. $43.01 $252.13B Buy
Article Searches
Is a Beat in Store for Cigna (CI) This Earnings Season? http://www.zacks.com/stock/news/405319/is-a-beat-in-store-for-cigna-ci-this-earnings-season?cid=CS-ZC-FT-405319 Apr 29, 2019 - Cigna's (CI) Q1 earnings should benefit from increase in revenues and membership.
3 Stocks Peter Lynch Would Love https://www.fool.com/investing/2019/04/29/3-stocks-peter-lynch-would-love.aspx?source=iedfolrf0000001 Apr 29, 2019 - They could be big winners for patient investors.
Why Earnings Season Could Be Great for Pfizer (PFE) http://www.zacks.com/stock/news/405127/why-earnings-season-could-be-great-for-pfizer-pfe?cid=CS-ZC-FT-405127 Apr 29, 2019 - Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock? http://www.zacks.com/stock/news/405277/sangamo-sgmo-q1-earnings-whats-in-store-for-the-stock?cid=CS-ZC-FT-405277 Apr 28, 2019 - For Sangamo's (SGMO) Q1, investor focus will be on its gene therapy candidate, SB-525, currently under evaluation for hemophilia A. The company also boasts several other early-stage promising candidates in its pipeline.
What's in Store for SS&C Technologies (SSNC) in Q1 Earnings? http://www.zacks.com/stock/news/403867/whats-in-store-for-ssc-technologies-ssnc-in-q1-earnings?cid=CS-ZC-FT-403867 Apr 25, 2019 - SS&C Technologies (SSNC) efforts to strengthen its cloud-based and AI technologies are likely to drive the top line.
Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates? http://www.zacks.com/stock/news/398971/pfizer-pfe-to-report-q1-earnings-will-it-beat-estimates?cid=CS-ZC-FT-398971 Apr 24, 2019 - While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Kidney-Cancer Market: Good for Patients, Hard for Investors https://www.fool.com/investing/2019/04/23/kidney-cancer-market-good-for-patients-hard-for-in.aspx?source=iedfolrf0000001 Apr 23, 2019 - Drugmakers battle for patients.
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release http://www.zacks.com/stock/news/391530/pfizer-pfe-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q1-release?cid=CS-ZC-FT-391530 Apr 23, 2019 - Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Bayer (BAYRY) This Earnings Season? http://www.zacks.com/stock/news/390421/whats-in-store-for-bayer-bayry-this-earnings-season?cid=CS-ZC-FT-390421 Apr 22, 2019 - Bayer (BAYRY) is expected to provide pipeline updates along with its first-quarter results.
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store? http://www.zacks.com/stock/news/390180/exact-sciences-exas-to-post-q1-earnings-whats-in-store?cid=CS-ZC-FT-390180 Apr 22, 2019 - During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.

Pages: 12345678...98

<<<Page 3>